Syndax Pharmaceuticals SNDX Proceeds from issuance of common stock relating to employee stock plans
Proceeds from issuance of common stock relating to employee stock plans at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's proceeds from issuance of common stock relating to employee stock plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's proceeds from issuance of common stock relating to employee stock plans?
- Syndax Pharmaceuticals (SNDX) reported proceeds from issuance of common stock relating to employee stock plans of $458K in Q1 2026.
- How has Syndax Pharmaceuticals's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
- Syndax Pharmaceuticals's proceeds from issuance of common stock relating to employee stock plans decreased by 16.0% year-over-year, from $545K to $458K.
- What is the long-term trend for Syndax Pharmaceuticals's proceeds from issuance of common stock relating to employee stock plans?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's proceeds from issuance of common stock relating to employee stock plans has grown at a 44.9% compound annual growth rate (CAGR), from $367K to $1.62M.